Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT - INTERIM ANALYSIS OF THE PHASE III CLINICAL TRIAL OF PENPULIMAB IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE SQUAMOUS NONSMALL CELL LUNG CANCER HAS REACHED KEY ENDPOINTS

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

Website:www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

INTERIM ANALYSIS OF THE PHASE III CLINICAL TRIAL OF

PENPULIMAB IN COMBINATION

WITH CHEMOTHERAPY FOR FIRST-LINE SQUAMOUS NONSMALL CELL

LUNG CANCER HAS REACHED KEY ENDPOINTS

The board of directors (the "Board") of Sino Biopharmaceutical Limited (the "Company", together with its subsidiaries, the "Group") announces that, the interim analysis of the phase III clinical trial of Penpulimab (product name: Annike (τ̵̙); research and development code:AK105), an anti-PD-1 monoclonal antibody drug jointly developed by the Company and Akeso, Inc. in combination with paclitaxel and carboplatin for first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer patients, has reached key research endpoints.

Upon the review by the Independent Data Monitoring Committee (IDMC), the interim analysis of the clinical trial demonstrates that, Penpulimab monoclonal antibody in combination with paclitaxel and carboplatin significantly reduces the progressive disease or risk of death as compared with placebo in combination with paclitaxel and carboplatin. Key research endpoints have reached the pre-defined efficacy boundary and the safety profile is consistent with the previously reported study results of Penpulimab monoclonal antibody and no new safety issues were found.

The Company and Akeso, Inc. intend to communicate with the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China in relation to the drug application of Penpulimab monoclonal antibody in combination with paclitaxel and carboplatin for first-line treatment of squamous non-small cell lung cancer.

By order of the Board

Sino Biopharmaceutical Limited

Tse, Theresa Y Y

Chairwoman

Hong Kong, 24 February 2021

As at the date of this announcement, the Board of the Company comprises nine Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five Independent NonExecutive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Mr. Li Kwok Tung Donald.